Bulent Ozpolat

6PUBLICATIONS
10CO-AUTHORS
Molecular targetsChemical engineering designCancer cell biologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 03, 2026
Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2-Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple-Negative Breast Cancer Therapy and Structure-Activity Relationship.

|Sep 07, 2023
Flavopiridol Suppresses Cell Proliferation and Migration and Induces Apoptotic Cell Death by Inhibiting Oncogenic FOXM1 Signaling in IDH Wild-Type and IDH-Mutant GBM Cells.

Ahsen Guler, Zuhal Hamurcu, Halil Ulutabanca

|Aug 25, 2022
Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.

Venhar Cınar, Zuhal Hamurcu, Ahsen Guler

|Jun 21, 2021
Correction to "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo".

Ferah Comert Onder, Nermin Kahraman, Esen Bellur Atici

|Jan 30, 2021
UV radiation resistance-associated gene (UVRAG) promotes cell proliferation, migration, invasion by regulating cyclin-dependent kinases (CDK) and integrin-β/Src signaling in breast cancer cells.

Sevide Sencan, Mine Tanriover, Mustafa Ulasli

|May 08, 2020
Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.

Didem Karakas, Bulent Ozpolat

Pageof 1

Frequent Collaborators

1 joint publications

Ali Cagir

1 joint publications

Serdar Durdagi

1 joint publications

Mehmet Ay

1 joint publications

Venhar Cınar